A drug cocktail that included Vertex Pharmaceuticals' telaprevir in a late-stage study cured about 65% of hepatitis C patients who had not responded to other therapies, compared with 17% of those given the standard combination of pegylated interferon and ribavirin. The best outcomes were seen in patients who previously had a relapse.

Related Summaries